Neumora Therapeutics reported a significantly narrowed net loss for the third quarter ended September 30, 2026, driven by a 44% reduction in research and development expenses. The company reached a critical milestone with the submission of an Investigational New Drug (IND) application for NMRA-215, a potential best-in-class NLRP3 inhibitor for obesity.
Key Highlights
- Research and development expenses decreased to $22.6 million from $40.5 million in the prior year period, reflecting lower clinical trial and personnel-related costs.
- Preclinical monotherapy data for NMRA-215 showed weight loss of up to 19% in diet-induced obesity mouse models, with efficacy increasing to 26% when combined with semaglutide.
- The company ended the quarter with $85.7 million in cash and cash equivalents, noting that while results show execution on the pipeline, substantial additional funding will be required to reach future inflection points.